Continuous wound infusion with chloroprocaine in a pig model of surgical lesion : Drug absorption and effects on inflammatory response by A. Massimo et al.
© 2017 Allegri et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. 
php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work 
you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For 
permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Journal of Pain Research  2017:10 2515–2524
Journal of Pain Research Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
2515
O R I G I N A L  R E S E A R C H
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/JPR.S139856
Continuous wound infusion with chloroprocaine 
in a pig model of surgical lesion: drug absorption 
and effects on inflammatory response
Massimo Allegri,1,2 Dario 
Bugada,1–3 Manuela De 
Gregori,2,4 Maria A Avanzini,5 
Annalisa De Silvestri,6 Anna 
Petroni,7 Angelo Sala,7,8 
Claudia Filisetti,9–11 Antonia 
Icaro Cornaglia,12 Lorenzo 
Cobianchi13,14
1Department of Medicine and Surgery, 
University of Parma, Parma 2SIMPAR 
Group (Study in Multidisciplinary 
PAin Research), 3Department of 
Anaesthesia and ICU, ASST Papa 
Giovanni XXIII, Bergamo, 4Pain 
Therapy Service, Fondazione IRCCS 
Policlinico San Matteo, 5Laboratory 
of Transplant Immunology/Cell 
Factory, IRCCS Foundation Policlinico 
San Matteo, 6Clinical epidemiology 
and Biometrics Unit, Fondazione 
IRCCS Policlinico San Matteo, Pavia, 
7Department of Pharmacological and 
Biomolecular Sciences, University 
of Milan, Milan, 8I.B.I.M., C.N.R., 
Palermo, 9PhD School, University 
of Pavia, 10Department of Pediatric 
Surgery, Fondazione IRCCS Policlinico 
San Matteo, Pavia, 11Department of 
Pediatric Surgery, “V. Buzzi” Children’s 
Hospital, Milan, 12Department of 
Public Health, Experimental and 
Forensic Medicine, University of Pavia, 
13Department of Surgical, Clinical, 
Paediatric and Diagnostic Science, 
University of Pavia, 14General Surgery 
1, IRCCS Fondazione Policlinico San 
Matteo, Pavia, Italy
Abstract: Continuous wound infusion (CWI) may protect from inflammation, hyperalgesia 
and persistent pain. Current local anesthetics display suboptimal pharmacokinetic profile during 
CWI; chloroprocaine (CP) has ideal characteristics, but has never been tested for CWI. We per-
formed an animal study to investigate the pharmacokinetic profile and anti-inflammatory effect 
of CP during CWI. A total of 14 piglets received an infusion catheter after pararectal laparotomy 
and were randomly allocated to one of three groups: 5 mL/h infusion of saline (group A), CP 
1.5% (group B) and CP 0.5% (group C). Blood sampling was performed to assess absorption 
and systemic inflammation at 0, 3, 6, 12, 24, 48, 72, 96, 102 and 108 hours. The wound and 
contralateral healthy abdominal wall were sampled for histological analyses. Absorption of CP 
from the site of infusion, evaluated as the plasmatic concentrations of CP and its metabolite, 
4-amino-2-chlorobenzoic acid (CABA), showed a peak during the first 6 hours, but both CP 
and its metabolite rapidly disappeared after stopping CP infusion. Local inflammation was 
reduced in groups B and C (CP-treated p < 0.001), in a CP dose-dependent fashion. While CP 
inhibited in a dose-dependent manner pig mononuclear cells (MNCs) in vitro proliferation to a 
polyclonal activator, no effect on systemic cytokines’ concentrations or on ex vivo monocytes’ 
responsiveness was observed, suggesting the lack of systemic effects, in line with the very short 
half-life of CP in plasma. CP showed a very good profile for use in CWI, with dose-dependent 
local anti-inflammatory effects, limited absorption and rapid clearance from the bloodstream 
upon discontinuation. No cytotoxicity or side effects were observed. CP, therefore, may represent 
an optimal choice for clinical CWI, adaptable to each patient’s need, and protective on wound 
inflammatory response (and hyperalgesia) after surgery.
Keywords: continuous wound infusion, pig model, chloroprocaine, pharmacokinetics, inflam-
mation, postoperative pain
Introduction
Postoperative analgesia still remains a challenge,1,2 and the importance of targeted 
treatments has often been stressed.3,4 Pain involves different mechanisms (peripheral 
nociception, central modulation and primary and secondary hyperalgesia), with noci-
ceptor’s activation being the trigger for all. Inflammation is the major background 
factor acting both peripherally and centrally on neural structures, leading to hyperal-
gesia and probably acting as a main factor toward the development of persistent pain 
after surgery.5,6
Since the choice of the analgesic strategy should be targeted on pain pathophysi-
ology,7 a rational approach to postoperative analgesia is to block the origin of pain 
cascade (namely peripheral nociception) and to prevent all pain-related events. Thus, 
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further to subjective pain relief, an effective, prolonged8 
nociceptive block should reduce inflammatory response9 and 
central sensitization.10,11
Continuous wound infusion (CWI) with local anesthet-
ics (LAs) has been documented as an effective technique 
for postoperative pain relief in several studies12 and com-
parable to epidural analgesia.13 LAs display local/systemic 
anti-inflammatory properties, even at low concentrations.14 
LAs reduce polymorphonuclear granulocytes’ (PMNs) 
adhesion in the surgical site and block leukotriene B4, a 
powerful chemotactic mediator. Lidocaine and ropivacaine 
reduce TNFa-induced upregulation of integrins (CD11b–
CD18) essential for endothelial adhesion and diapedesis 
into the injured tissue; lidocaine and tetracaine cause loss 
of PMNs’ round shape necessary for adhesion. The global 
effect is the reduction of PMNs’ accumulation in the surgi-
cal wound, together with the release of local inflammatory 
chemokines.14
Currently, drugs used for CWI are long-lasting LAs, 
such as ropivacaine, bupivacaine, and levobupivacaine. Such 
drugs are considered safe at clinical doses, and the kinetic 
profile and blood levels have already been investigated during 
epidural infusions.15
However, both from a clinical and a pharmacokinetic 
perspective, an ultra short-acting LA may be more appro-
priate for CWI, as it could be better modulated according to 
specific patients’ needs with “on/off ” profile.
Chloroprocaine (CP) has fast onset (6–10 minutes) and 
short action (around 90 minutes),16 with a cholinesterase-
based plasmatic metabolism. Early cases of toxicity after 
spinal anesthesia17 were documented, but were related to the 
sodium bisulfite antioxidant and to the solution’s low pH.18 
Nowadays, antioxidant-free, safer preparations are available, 
and interest has grown again because of CP’s ideal profile 
for CWI.
There is no study, to our knowledge, investigating CP 
during intrawound continuous infusion in an animal model; 
moreover, there are few data elucidating the effect on local 
and systemic inflammation of a continuous subfascial wound 
infusion of LAs and in particular for CP.
As recently underlined by Gigliuto et al,19 a large animal 
model could be more appropriate than others to produce reli-
able translational results. We therefore evaluated the absorp-
tion associated with a continuous CP intrawound (subfascial) 
infusion in pig. We also investigated if CP at two different 
dosages may influence local and systemic inflammatory 
responses after surgical lesion both in vivo and ex vivo.
Materials and methods
All animal procedures were performed according to the 
protocol approved by Institutional Animal Care and Use 
Committee (IACUC) – University of Pavia. All animal care 
and experimental procedures followed local, national and 
European Union guidelines for the animals’ use (Directive 
2010/63/EU – revising Directive 86/609/EEC on the protec-
tion of animals used for scientific purposes).
Animals and surgical procedures
Piglets (20–30 kg) underwent pararectal laparotomy, 
extended for 10 cm. The parietal peritoneal membrane was 
then closed with a continuous absorbable synthetic suture. 
An intrawound, multiholed catheter (PAINFusor® – Plan-
1-Health, Udine, Italy) was placed between peritoneum and 
deep muscular fascia along the length of the wound and 
tunneled subcutaneously. Muscle layers and skin were finally 
closed with a continuous absorbable synthetic suture.
Surgical procedure was performed under general bal-
anced anesthesia, including mechanical ventilation via 
orotracheal intubation and mioresolution.20,21 A central 
venous catheter was placed in the right external jugular vein 
with open surgical technique and was used for drug infusion 
and for blood sampling. At the end of surgical procedures, 
piglets were set in the metabolic cage and were supplied 
with water and standard bran. Intravenous antibiotic (cefazo-
lin 1 g) and omeprazole 40 mg were administered during 
follow-up to prevent wound infections and stress-induced 
gastric ulcerations. Analgesia was performed in all animals 
by intramuscular injection of tramadol 50 mg during the 
perioperative period, with no additional analgesics, according 
to our animal protocols for surgical trials.
Animals were randomly allocated to 3 groups with a 5 mL/h 
continuous infusion through elastomeric pump for 72 hours: 
saline (group A), CP 1.5% (group B) or CP 0.5% (group C). 
The randomization was based on a computer-generated list.
Sample collection
During the follow-up period, peripheral blood was collected 
for the determination of CP and its metabolite, as well as of 
the effects on systemic inflammation, at 0, 3, 6, 12, 24, 48, 
72, 96, 102 and 108 hours from incision. Plasma was obtained 
by centrifugation at 3000 rpm for 15 minutes and stored at 
–20°C until analysis. Mononuclear cells (MNCs), for in vitro 
and ex vivo experiments, were obtained by gradient density 
on cell separation media (Cedarlane, Burlington, USA) at 
2500 rpm for 20 minutes. The catheter was removed after 
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96 hours of infusion. Piglets were finally sacrificed, according 
to international guidelines.
Determination of CP and its metabolite 
in plasma
CP and its metabolite 4-amino-2-chlorobenzoic acid (CABA) 
were analyzed by liquid chromatography/tandem mass spec-
trometry using a high performance liquid chromatography 
(HPLC) Agilent (model 1200) equipped with an autosam-
pler (PAL HTS-xt; PAL System, CTC Analytics, Zwingen, 
Switzerland) directly interfaced with a triple-quadruple 
API 4000 (AB Sciex, Framingham, MA, USA), equipped 
with an electrospray ionization (ESI) source.22,23 CP was 
provided by Sintetica SrL, (Mendrisio, Switzerland) CABA 
by Sigma-Aldrich Co. (St Louis, MO, USA) and deuterated 
PABA (4-aminobenzoic acid), used as internal standard (IS) 
for chloroprocaine and CABA quantitation, by Santa Cruz 
Biotechnology Inc., Dallas, TX, USA. Methanol and formic 
acid were from Sigma-Aldrich, whereas HPLC grade water 
was obtained using a Milli Q water purification system. 
Chromatographic separation was carried out using a Syn-
ergi 4 micro-Hydro-RP 80 A, 150 × 2 mm × 4 µm column 
(Phenomenex, Torrance, CA, USA) at a flow rate of 200 µL/
min. A total of 10 µL of the sample was injected in a linear 
gradient system from 85% of solvent A (0.1% formic acid in 
water) to 90% of solvent B (0.1% formic acid in methanol) 
over 3 minutes. Final conditions were held for 3 minutes 
before equilibration back at starting conditions.
The triple-quadruple was operated in positive ions mode 
for multiple reaction monitoring (MRM). The following 
characteristic fragmentations were used for identification and 
quantitative analyses: CP from m/z 272 to 198.6 or 153.9, 
CABA from m/z 172.2 to 128 or 153.9, and d
4
-PABA from 
m/z 142.1 to 98.8 or 123.9. The most abundant transition was 
used for quantitative analysis, while the second transition was 
used as qualifier for additional identification purposes. A total 
of 100 µL of plasma samples were added with 20 µL (1 ng/µL) 
IS and 400 µL of methanol; samples were then put at –20°C 
overnight. After centrifugation at 13,000 rpm for 10 minutes, 
450 µL of the solution were recovered and evaporated using 
a rotary evaporator. Finally, the samples were resuspended 
in 100 µL of water/methanol (1:1) and 10 µL was used for 
liquid chromatography/tandem mass spectrometry analy-
sis. The calibration curves were prepared in drug-free pig 
plasma, from working solutions of CP and CABA of 1, 3, 
10, 30, 100 and 300 ng/mL and processed as the biological 
samples. Calibration curves were obtained plotting the ratio 
of the chromatographic area of specific transitions for the 
compounds of interest over that of specific transition of the 
internal standard, and the correlation coefficient was always 
better than 0.99. The limit of quantification (LOQ) was 1 ng/
mL of plasma for both compounds.
Data were acquired and processed using Analyst 1.6.1. 
Concentrations are presented as mean and standard error of 
the mean of n determinations.
Histopathological analysis
For histological examination, 3 samples of the full-thickness 
wound and 1 sample of the contralateral healthy abdominal 
wall were collected from each animal. Each sample was 
0.5 cm thick. The samples were fixed in 4% neutral buffered 
formalin for 48 hours, dehydrated with gradient alcohol 
series, cleared in xylene and eventually embedded in paraffin. 
Serial sections (8 µm) were obtained using a Leitz (Wetzlar, 
Germany) microtome, stained with hematoxylin and eosin 
(H&E) and examined with a Zeiss (Oberkochen, Germany) 
Axiophot microscope.
We evaluated the presence of inflammatory cells: neutro-
phils, eosinophils, lymphocytes, macrophages and mast cells, in 
pericatheter blank tissues. A total of 15 sections were evaluated 
for statistical analysis (4 sections per group – corresponding to a 
different animal of each experimental group plus 1 contralateral 
healthy sample per group). For each section, at least 8 randomly 
determined areas of connective tissue were examined at 20× 
magnification and 100 cells per area were counted. The rate of 
inflammatory cells was assessed using a semiquantitative scale, 
with scores ranging from 0 to 4 by 3 independent observers 
(Table 1). Histological scores are reported as median and 25–75 
percentile (interquartile range, IQR).
Systemic inflammation analysis
Systemic inflammation was evaluated by quantifying pig 
interleukin-6 (pIL-6), pIL-10, pIL-8, pIL-1β and pig inter-
feron (pIFN)-γ levels in plasma samples at each time point, 
after incision in all animals, by commercially available 
quantitative enzyme-linked immunosorbent assay (ELISA) 
(Quantikine; R&D Systems, Inc., Minneapolis, MN, USA). 
Detection limits were as follows: 18.8 pg/mL for pIL-6, 
31.3 pg/mL for pIL-10, 62.5 pg/mL for pIL-8, 39.1 pg/mL 
for pIL-1β and 39 pg/mL for pIFN-γ.
Table 1 Semiquantitative score used for the assessment of the 
percentage of the inflammatory infiltrate
Score Percentage of inflammatory infiltrate
0 0–10
1 10–25
2 25–50
3 50–75
4 >75
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In vitro and ex vivo cell proliferation 
suppression
In order to evaluate in vitro cell proliferation suppression, CP 
and CABA were added at different concentrations (from 1.25 
to 0.02 mg/mL) to resting and phytohemagglutinin (PHA)-
activated MNCs obtained before treatment. In detail, 105 
MNCs/well were plated in triplicate in flat-bottom microwells 
(Corning Costar, Euroclone, Milan, Italy), in RPMI 1640 
medium (ThermoFisher Scientific, Waltham, MA, USA), 
10% fetal calf serum (Euroclone, Celbio), without (resting) 
or with PHA (activated) (4  g/mL; Boehringer Ingelheim, 
Mannheim, Germany). After a 3-day incubation at 37°C in 
a humidified 5% CO
2 
atmosphere,3 H-thymidine (3HTdR 0.5 
mCi/well; Amersham, Buckinghamshire, UK) incorporation 
was measured during the last 21 hours by standard procedure. 
Results were expressed as stimulation index (SI = cpm stimu-
lated/cpm unstimulated) and reported as residual proliferation.
Moreover, in order to define if CP in vivo treatment 
induced a change in cell response capability we evaluated ex 
vivo, with the same methodology, the effects of CP treatment 
on the response to PHA of MNCs obtained at different time 
points (basal, 96 and 108 hours) of pharmacological treat-
ment in groups A (saline), B (CP 1.5%) and C (CP 0.5%).
Cell viability
To test if CP and CABA could affect MNCs viability, after 
in vitro culture, cells were evaluated by Trypan blue (Sigma, 
Milan, Italy) exclusion test. Percentage of cell viability is 
calculated as (number of viable cells/total number of cells 
[viable + nonviable] × 100).
Statistical analysis
Cytokine concentrations were compared between groups with 
analysis of variance for repeated measure. An ordinal logistic 
regression model was fitted using histological score as depen-
dent variable and group as independent variable. To compare all 
groups, post hoc estimation (between doses or between groups 
B and C and group A) and Wald tests were also performed. A 
p-value <0.05 was considered statistically significant.
Quantitative variables are described as mean and SD. 
Comparisons between groups (A and B, C) and time were 
performed by means of analysis of variance for repeated 
measures. The same method was applied to analyze SI at dif-
ferent CP and CABA concentrations. Robust standard errors 
were considered to take into account the clustered nature of 
the data. A p-value <0.05 was considered significant. Stata 
v14.1 (StataCorp LP, College Station, TX, USA) was used 
for all the analyses.
We did not perform a power analysis since previous litera-
ture does not provide data to support any power calculation. 
The present study is to be considered as a pilot study.
Results
Four animals (25–30 kg, average weight 29.6 kg) were 
randomly allocated to each group; in group A 2 additional 
animals were studied as 2 animals were excluded as they 
developed fever and wound infections. All the other animals 
in groups B and C completed the follow-up period unevent-
fully, and they were all treated without any deviation from 
the protocol.
We did not register any adverse effect or allergic reaction 
in all the animals used for the study.
Concentrations of CP and its metabolites 
in plasma
Concentrations of CP were mostly below the quantitation 
limit, with only 6 blood samples showing the presence of 
very low concentrations of the intact molecule (1–2.3 ng/
mL in animals perfused with CP 0.5%, and 1–20.8 ng/mL 
in animals perfused with CP 1.5%). CABA concentrations 
showed a sharp increase immediately after the infusion was 
started, peaking between 3 and 6 hours from the beginning 
of the infusion, and returning to basal level (zero) as soon 
as the continuous infusion was stopped (Figure 1). The peak 
in CABA concentrations appeared to be proportional to the 
concentration of CP infused (Figure 1), averaging 177±141 
and 543±169 ng/mL in animals perfused with CP 0.5% and 
1.5%, respectively.
Histopathological analysis
The presence of inflammatory cells was significantly higher 
in group A than in groups B and C (p < 0.001, in both cases). 
These results are well summarized by semiquantitative scores 
(Table 2) that show a dose-dependent reduction of the inflam-
matory infiltrate within the wound, which is nearly halved 
with higher CP doses.
This reduction is even more evident in wound sections, 
where refined analyses on tissue damage and reaction are 
possible: pigs in group A (saline) have high amounts of 
leukocytes and lymphocytes infiltrating wound layers up 
to connective tissue, and cells surrounding the catheter’s 
blank display signs of necrosis (Figure 2). Signs of cell dam-
age are less evident in CP-infused pigs, and inflammatory 
infiltrates are less pronounced and different in nature (less 
leukocytes); inflammation reaches the connective tissue to a 
lesser extent, and signs suggestive of tissue regeneration are 
 
Jo
ur
na
l o
f P
ai
n 
Re
se
ar
ch
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
2.
39
.5
6.
90
 o
n 
28
-N
ov
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Journal of Pain Research  2017:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2519
Continuous wound infusion with CP
Figure 1 CABA plasma concentrations after continuous infusion with 0.5% (closed squares) and 1.5% (closed diamond) of chloroprocaine. 
Note: CABA was measured by liquid chromatography/tandem mass spectrometry as described in the “Materials and methods” section. Data are expressed as mean and 
SEM (n = 4).
Abbreviations: CABA, 4-amino-2-chlorobenzoic acid; CP, chloroprocaine; SEM, standard error of the mean; h, hours.
800
600
400
CA
BA
 n
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m
L
200
0
0 3 6 12 24 48
Time (h)
CP 1.5%
CP 0.5%
72 96 102 108
Table 2 Trend of the inflammatory infiltrate scores among the different treatments
Group Catheter surrounding area (1 cm): median (IQR) Contralateral area median (IQR)
A (Saline 0.9%) 4 (3–4) 0 (0–1)
B (CP 1.5%) 2 (1–2) 0 (0–1)
C (CP 0.5%) 3 (2–3) 0 (0–1)
Abbreviations: CP, chloroprocaine; IQR, interquartile range.
Figure 2 Group A (saline) animal.
Notes: (A) Catheter blank (white in the picture) surrounded by connective tissue. A large amount of inflammatory infiltrate is evident, mostly round cells such as 
lymphocytes and some PMNs. (Inset) Right next to the blank, many cells appear pale as if suffering or necrotic; collagen fibers are contracted. Many red blood cells are 
present, probably due to the catheter extraction. (B) Inflammation reaches the cutaneous connective tissue, while (C) a great number of leukocytes surround muscular 
fibers (D) and contralateral healthy skin appears normal.
Abbreviations: CP, chloroprocaine; PMN, polymorphonuclear granulocyte.
A B
C
D
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evident ( Figure 3). The reduction in inflammatory infiltrates 
and signs of tissue regeneration are more evident with higher 
doses of CP (Figure 4), however no statistically significant 
difference was observed between groups B and C (Table 2).
Systemic inflammatory analysis
Plasma cytokine quantification at different time points did 
not reveal any statistical differences between groups B and 
C versus group A, respectively, for the pro-inflammatory 
Figure 3 Group B (CP 1.5%) animal.
Notes: (A) Connective wall surrounding the blank shows no structural damage in comparison with controls; inflammatory infiltrate appears less evident, just few leukocytes 
are present, mostly lymphocytes; (inset) fibroblasts look plump and basophilic; collagen bundles are thin with an irregular arrangement and some tiny blood vessels are 
evident, suggesting tissue repair. (B) Cutaneous tissues contain a slightly higher amount of infiltrate than contralateral healthy skin (D). (C) Muscular fibers are surrounded 
by few leukocytes.
Abbreviation: CP, chloroprocaine.
A
C D
B
Figure 4 Group C (CP 0.5%) animal.
Notes: (A) Connective tissue of the blank wall contains active basophilic fibroblasts, thin collagen bundles and a number of round white blood cells (inset); (B) mild 
inflammatory infiltrate affects dermal papillae and (C) intramuscular connective. (D) Contralateral healthy skin appears normal.
Abbreviation: CP, chloroprocaine.
A
C
B
D
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cytokines’ levels (IL-1β, p = 0.8 and 0.4; IL-6, p = 0.7 and 
0.9; IL-8, p = 0.6 and 0.6; IFN-γ, p = 0.06 and 0.2) and those 
of the anti-inflammatory ones (IL-10, p = 0.3 and 0.3) during 
the entire follow-up period (Figure 5).
In vitro and ex vivo cell proliferation 
analyses
The effect of CP and its metabolite on the in vitro prolifera-
tion of pig MNCs stimulated with PHA was evaluated at 
different concentrations in 4 animals using MNCs obtained 
before any kind of surgical procedure and treatment. The 
results are shown in Figure 6.
PHA-stimulated proliferation of MNCs was significantly 
reduced by the addition of 1.25 and 0.6 mg/mL of CP, with 
a direct correlation between the concentrations and the 
degree of inhibition. A decrease in proliferation was also 
observed for CABA at 1.25 mg/mL, but it was not statisti-
cally  significant (p = 0.1).
Figure 5 Trend of the blood cytokines levels in the three experimental groups.
Notes: Group A, saline; Group B, CP 1.5%; Group C, CP 0.5%.
Abbreviations: CP, chloroprocaine; IL, interleukin; IFN, interferon.
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Evaluation of cell viability, by Trypan blue exclusion test, 
showed that the addition of CP and CABA to in vitro resting 
and activated pig MNCs did not cause cell death, even at the 
highest concentration (percentage of viable cells 72% and 
79%, respectively), suggesting the lack of cytotoxic activity 
of CP and its metabolite. Moreover, CP and CABA did not 
induce in vitro cell proliferation at any concentrations of 
resting MNCs, indicating no antigenic activity.
In order to assess the effect of CP and CABA we evaluated 
ex vivo the response to PHA of MNCs isolated from blood 
collected at different time points (basal, 96 and 108 hours). 
Results did not show any significant differences between 
group A versus group B (p = 0.22) and versus group C 
(p = 0.34) at each time point.
Figure 6 Treatment group in vitro proliferation.
Notes: In vitro cell proliferation suppression by CP (A) and its metabolite (B) at different concentrations, on PHA-activated pig MNCs. Results are expressed as residual 
proliferation. CP induces significant reduction at concentration of 1.25 mg/mL (*p = 0.012) and of 0.6 mg/mL (**p = 0.052). (C) In vitro PHA-induced proliferation of MNCs 
obtained from group A, B, C animals at different time points (gray bars = T0, black bars = 96 hours and white bars = 108 hours). Results are expressed as stimulation index. 
No significant differences are observed between treated and control groups. Group A, saline; Group B, CP 1.5%; Group C, CP 0.5%.
Abbreviations: CP, chloroprocaine; MNCs, mononuclear cells; PHA, phytohemagglutinin.
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Discussion
So far, long-acting LAs have mainly been used for CWI, 
despite their suboptimal pharmacokinetic profile and the lack 
of studies investigating their systemic exposure.
New formulations of CP, an ultrashort acting LA with 
plasmatic pseudocholinesterase metabolism, theoretically 
display an ideal pharmacokinetic profile for CWI. In a trans-
lational perspective, and responding to the need of testing 
this molecule in an experimental setting, we investigated the 
use of CP in a large animal model (pig).
The current investigation confirmed the hypothesis that 
CWI in our large animal model would result in relatively low 
amounts of CP being absorbed, and in light of the extremely 
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short half-life of CP in plasma may definitely limit the pos-
sibility of systemic effects: indeed during the 96 hours of 
5 mL/h continuous administration of both 0.5% and 1.5% 
CP, the overall amount of CP penetrating the systemic cir-
culation (that is plasma concentrations of CP + its plasmatic 
metabolite CABA) reached an average C
max
 at least 10-fold 
lower than that observed in obstetric patients receiving epi-
dural CP during cesarian section.24 A dose-related increase 
in concentrations was observed after the beginning of the 
CWI and up to 6 hours, suggesting an initial blood vessel-
dilating response to CP,25 resulting in a peak of absorption that 
appeared to progressively decrease over time. We registered 
no side effects or allergic reaction in any of the enrolled 
animals. Our study confirms CP as an ideal local anesthetic 
for CWI, due to its fast catabolism, safety and on/off profile.
The lack of a cholinesterase inhibitor at collection pre-
vents the actual assessment of systemic exposure to intact 
CP since CP degradation occurs very rapidly in plasma, but 
reporting the total amount of CP entering the bloodstream 
(that is CP + CABA) our study reliably describes the overall 
absorption of CP upon CWI, showing concentrations well 
below those observed upon epidural administration during 
either cesarean section or vaginal delivery,24 peaking between 
3 and 6 hours and decreasing to undetectable levels after 
infusion was suspended. Therefore, also taking into account 
potential differences in esterase activities between the 
 experimental animal used and humans, the systemic expo-
sure to CP appeared very limited, as confirmed by the lack 
of effects on inflammatory parameters or blood cell activity. 
Indeed no correlation was detected between treatment and 
systemic inflammation, as assessed by determination of 
plasma concentrations of pro-inflammatory cytokines, sug-
gesting that only local inflammation was modulated by the 
presence of CP. Additionally, local infusion of CP did not 
affect the ex vivo response of immune cells obtained from 
treated animals, even if PHA-induced proliferation of MNCs 
was suppressed by in vitro addition of CP, further supporting 
the lack of significant circulating concentrations of intact CP 
as suggested by the relatively low plasmatic concentrations 
of CABA.
Our data also suggest that the continuous infusion with 
CP displays local anti-inflammatory effects. These effects 
were dose-dependent, as we observed a more pronounced 
reduction of inflammatory response in the group treated with 
higher concentrations of local anesthetic. Since we did not 
monitor pain, we cannot determine if the dose-dependent 
anti-inflammatory effect is associated with either better pain 
relief, or with a more pronounced reduction of neurogenic 
inflammation or with specific anti-inflammatory effect of CP. 
Investigating the pain response would have provided addi-
tional support to our studies, but measuring pain in a large 
animal model can be very challenging, and a well-accepted 
model is still lacking. Nevertheless, apart from the assess-
ment of the analgesic effect, our study was able to confirm 
in a large animal model results previously obtained only in 
small animals,26,27 ie, the ability of nociceptive block to reduce 
local inflammation. In consideration of the promising results 
relative to the limited absorption and the anti-inflammatory 
effect of CP obtained with this study, future trials are war-
ranted to address this topic.
Despite the low sample size (typical of studies in big 
animal models19), we confirmed the limited absorption and 
a local anti-inflammatory activity of CWI with CP. Once 
these results are confirmed in humans, they may show CP 
to be a good choice for CWI allowing immediate analgesic 
benefit and fast elimination; patients with liver or kidney 
diseases may take advantage of rapid plasmatic clearance 
of CP, preventing accumulation and toxicity. Clinical stud-
ies are needed to define the lowest effective dose of CP and 
investigate its anti-inflammatory effect in a human model.
Conclusion
This pilot study on CP continuous infusion in a large animal 
model may display future translational value. Once confirmed 
in humans, our data may show CP to be a first-line choice 
for CWI, with limited systemic exposure, high compliance 
to the needs of each patient and potential applications to a 
broad spectrum of clinical situations. The dose-dependent 
anti-inflammatory effect may have clinical relevance in pain 
medicine, showing CP to be an interesting target for future 
clinical applications and research purposes.
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